Our prospective study demonstrated that simultaneous 18F-fluciclovine PET/MRI can detect lymph node, prostatic and bone lesions suspicious for prostate cancer recurrence in patients with a wide range of PSA levels. The gene discussed is KLK3; the disease is prostate cancer.